Skip to main content
letter
. 2020 Jan 15;201(2):250–253. doi: 10.1164/rccm.201907-1343LE

Table 1.

Baseline Characteristics, Outcomes, and Preliminary Biomarker Analysis by Interstitial Lung Disease Subtype

Baseline Characteristics CTD-ILD* (n = 148) CHP (n = 98) U-ILD (n = 159)
 Center, n (%)  
 
 
  University of California, Davis 83 (56.1)
60 (61.2)
93 (58.5)
  University of Chicago 65 (43.9)
38 (38.8)
66 (41.5)
 Age, mean ± SD 61 ± 13.8
67.9 ± 9.7
68.5 ± 11.1
 Male sex, n (%) 48 (32.4)
49 (50)
81 (50.9)
 Race, n (%)  
 
 
  White 80 (54)
71 (72.4)
120 (75.4)
  African American 28 (18.9)
4 (4.1)
14 (8.8)
  Hispanic 26 (17.6)
11 (11.2)
6 (3.8)
  Asian 8 (5.4)
3 (3.1)
6 (3.8)
  Other/unknown 6 (4.1)
9 (9.2)
13 (8.2)
 Ever smoker, n (%) 69 (46.6)
52 (53.1)
90 (57)
 Lung function  
 
 
  FVC% predicted, mean ± SD 67.2 ± 19
66.5 ± 20
69.1 ± 20
  DlCO% predicted, mean ± SD 50.4 ± 18.9
55.1 ± 20.3
52.3 ± 21.1
 Immunosuppressive therapy, n (%)§ 90 (60.8)
42 (42.9)
53 (33.3)
  Immunosuppressive exposure months, median (IQR) 24 (11–24)
11.5 (5.5–24)
12 (6.7–24)
 GAP-ILD score, mean ± SD 1.4 ± 1.3
1.8 ± 1.6
3.7 ± 1.6
   
 
 
Outcomes  
 
 
 Death, n (%) 17 (11.5)
21 (21.4)
37 (23.3)
 Lung transplant, n (%) 2 (1.4)
2 (2.1)
3 (1.9)
 ≥10% FVC decline, n (%) 21 (14.2)
32 (32.7)
29 (18.2)
 Follow-up months, median (IQR) 12.7 (6.1–23.8) 11 (6.8–19) 11.2 (4.6–20.8)
  CTD-ILD* (n = 148)
CHP (n = 98)
U-ILD (n = 159)
Preliminary biomarker analysis Threshold HR (95% CI) Threshold HR (95% CI) Threshold HR (95% CI)
 CXCL13 525 pg/ml 4.78 (2.23–10.22) 140 pg/ml 2.2 (1.22–3.96) 107 pg/ml 3.17 (1.63–6.15)
 CA-125 90 pg/ml 3.31 (1.71–6.42) 46 pg/ml 1.83 (1.01–3.29) 117 pg/ml 3.42 (1.66–7.07)
 MMP7 7.9 ng/ml 2.27 (1.0–5.17) 6.5 ng/ml 2.33 (1.27–4.28) 4.7 ng/ml 2.26 (1.32–3.85)
 YKL-40 80 ng/ml 2.18 (1.12–4.24) 58 ng/ml 2.05 (1.14–3.71) 30 ng/ml 1.97 (0.96–4.03)
 SP-D 34 ng/ml 0.41 (0.15–1.16) 25 ng/ml 1.7 (0.89–3.25) 21 ng/ml 2.42 (1.27–4.59)
 VCAM-1 2,116 ng/ml 3.66 (1.6–8.4) 1,277 ng/ml 4.12 (2.14–7.95) 1,887 ng/ml 2.34 (1.0–5.49)

Definition of abbreviations: CHP = chronic hypersensitivity pneumonitis; CI = confidence interval; CTD-ILD = connective tissue disease–associated interstitial lung disease; GAP-ILD = gender, age, physiology ILD score; HR = hazard ratio; IQR = interquartile range; U-ILD = unclassifiable interstitial lung disease.

*

n when values were missing (FVC = 140; DlCO = 135; GAP-ILD n = 140).

n when values were missing (DlCO = 90).

n when values were missing (ever smoker = 158; FVC = 156; DlCO = 144; GAP-ILD = 156).

§

Mycophenolate mofetil, azathioprine, cyclophosphamide, and/or rituximab.

Advanced for final analysis based on Cox model Wald P < 0.008, which adjusted for multiple testing.